Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD

References

• National Heart, Lung and Blood Institute. Chronic obstructive pulmonary disease data fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, NIH, NHLBI, 2003. Available at: www.uptakemedical.com/pdfs/copd_fact.pdf. Accessed February 28, 2011
   Google Scholar
• Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-64
   PubMedGoogle Scholar
• Kochanek KD, Xu J, Murphy SL, et al. Deaths: preliminary data for 2009. National Vital Statistics Reports 2011;59:1-51
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Update 2009). Available at: http://www.goldcopd.org/. Accessed March 3, 2010
   Google Scholar
• Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005;366:563-71
   PubMed Web of Science ®Google Scholar
• Calverly PMA, Rabe KF, Goehring U-M, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
   PubMed Web of Science ®Google Scholar
• Rutten-van Mölken MPMH, Oostenbrink JB, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-35
   PubMed Web of Science ®Google Scholar
• Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005;23:619-37
   PubMed Web of Science ®Google Scholar
• Borg S, Ericcson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005;26:223-33
   PubMed Web of Science ®Google Scholar
• Dal NR, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2:169-76
   PubMedGoogle Scholar
• Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64
   PubMed Web of Science ®Google Scholar
• McDowell MA, Fryar CD, Ogden CL, et al. Anthropometric reference data for children and adults: United States, 2003–2006 in National Health Statistics Reports, October 10, 2008
   Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship Between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004;116:325-31
   PubMed Web of Science ®Google Scholar
• Mannino D. Chronic obstructive pulmonary disease: epidemiology and evaluation. Hospital Physician 2001;37:22-31
   Google Scholar
• Bateman ED, Rabe KF, Calverly PM, et al. Roflumilast with long-acting {beta}2 agonists for COPD: influence of exacerbation history. Eur Respir J 2011;38:553-60
   Google Scholar
• Hanania NA, Bateman ED, Calverley PM, et al. Benefits of Roflumilast Treatment on exacerbation outcomes in patients with COPD: pooled results from two pivotal 12-month studies. Presented at CHEST Annual Meeting Oct-Nov 2010, Vancouver, Canada
   Google Scholar
• Yu AP, Yang H, Wu EQ, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011;14:315-23
   PubMedGoogle Scholar
• Oostenbrink JB, Rutten-van Mölken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46
   PubMed Web of Science ®Google Scholar
• Nielsen R, Johannessen A, Askildsen JE, et al. The excess treatment-related costs of COPD by severity. A twelve-month follow-up study. Am J Respir Crit Care Med 2010;181:A4121
   Google Scholar
• Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002;122:1994-2002
   PubMed Web of Science ®Google Scholar
• Wennberg JE, Fisher ES, Sharp SM, et al. The care of patients with severe chronic illness: an online report on the Medicare Program by the Dartmouth Atlas Project; The Dartmouth Atlas of Health Care 2006. Available at http://www.dartmouthatlas.org/atlases/2006_Chronic_Care_Atlas.pdf. Accessed March 22, 2010
   Google Scholar
• EQ-5D: a standardised instrument for use as a measure if health outcome. Available at http://www.euroqol.org/home.html. [Last accessed 13 March, 2011]
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press, 2006
   Google Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117(2 Suppl):5S-9S
   PubMed Web of Science ®Google Scholar
• Brown WM. Treating COPD with PDE 4 inhibitors. Int J Chron Obstruct Pulmon Dis 2007;2:517-33
   PubMedGoogle Scholar